Supernus Pharmaceuticals, Inc. /
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. agrees to buy Navitor Pharmaceuticals, Inc.




Source for the buyer and target: Supernus Pharmaceuticals, Inc.
For the buyer and target.
“On April 1, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Agreement”), together with related ancillary transaction documents, with Navitor Pharmaceuticals, Inc., a Delaware corporation (“Navitor”), Navitor Pharmaceuticals, LLC, a Delaware limited liability company (“Navitor Parent,” and, together with Navitor, the “Sellers”).”
Published 7 Apr 2026
Open the sourceWhat happened
Supernus Pharmaceuticals, Inc. agreed to acquire Navitor Pharmaceuticals, Inc. for up to $350 million, according to a filing dated April 7, 2026. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Supernus Pharmaceuticals, Inc. agrees to buy Navitor Pharmaceuticals, Inc.
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Announced
“Supernus Pharmaceuticals, Inc. agrees to buy Navitor Pharmaceuticals, Inc. Supernus Pharmaceuticals, Inc. agreed to acquire Navitor Pharmaceuticals, Inc. for up to $350 million, according to a filing dated April 7, 2026”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly